Posted by Michael Wonder on 06 Apr 2022
Inside a campaign to get Medicare coverage for a new Alzheimer’s drug
6 April 2022 - The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.
Biogen’s Aduhelm is the first new drug approved for Alzheimer’s in 18 years, but is controversial because it has safety risks and whether it works is unclear.
